Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for Upfront $850 Million
By Ian Walker
Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.
The U.S. clinical-stage biotechnology company said Monday that Genentech will pay further sums based on certain pre-determined development, regulatory and commercial milestones being met.
As part of the deal Genentech will be responsible for clinical development, manufacturing and worldwide commercialization of the inhibitors, while Regor will continue to manage two current Phase 1 trials.
Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity, the company said.
The deal is expected to close in the fourth quarter of this year, subject to the usual conditions.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
September 30, 2024 01:44 ET (05:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
United States